This article was originally published in The Gray Sheet
Gains investigational device exemption for animal protein-based surgical adhesive BioGlue. The study, which is scheduled to begin as early as July, will include about 300 patients at 20 sites in the U.S. CryoLife expects the trials to be completed in 18-24 months, at which time the firm will submit a premarket approval application to FDA. In January, BioGlue gained a CE mark for vascular sealing and reconstruction surgeries
You may also be interested in...
Suspension of heartburn remedy ranitidine looming in the EU as the European Medicines Agency stands by its original decision.
Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.